natgillin/translations-raw huggingface dataset:
Dosage: Ovarian and Small Cell Lung Carcinoma
Doziranje: rak jajnika i rak pluća malih stanica
Dosage: Paediatric population
Doziranje: pedijatrijska populacija
Dosage: Treatment of Tumour-induced Hypercalcaemia
Doziranje: Liječenje hiperkalcijemije nastale zbog tumora
Dosages
Doze
Dosages above this produced 92% and 98% reductions of survival and lactation indices, respectively, as well as reductions in pup body weights.
Doze više od ovih, dovele su do sniženja indeksa preživljenja za 92% i laktacije za 98%, kao i do smanjenja tjelesne težine mladunčadi.
Dosages of 180 mg/m2 four times daily in children produced similar systemic exposure (24 hour AUC 40.0 h μM or 10.7 h μg/ml) as doses of 200 mg six times daily in adults (40.7 h μM or 10.9 h μg/ml).
180 mg/m2 četiri puta dnevno imao je sličnu sistemsku izloženost (24-satna ukupna bioraspoloživost AUC 40,0 h μM ili 10,7 h μg/ml), kao i doza od 200 mg šest puta dnevno primijenjene u odraslih (40,7 h μM ili 10,9 h μg/ml).
Dosages of 180 mg/m2 four times daily in children produced similar systemic exposure (24 hour AUC 40.0 h M or 10.7 h g/ml) as doses of 200 mg six times daily in adults (40.7 h M or 10.9 h g/ml).
Lijek primijenjen u djece u dozi od 180 mg/m2 četiri puta dnevno imao je sličnu sistemsku izloženost (24-satna ukupna bioraspoloživost AUC 40,0 h μM ili 10,7 h μg/ml), kao i doza od 200 mg šest puta dnevno primijenjene u odraslih (40,7 h μM ili 10,9 h μg/ml).
Dosages of the above studies, covering 83 patients, indicate that dosing guidelines for adult subjects are also valid for neonatal and paediatric patient population.
Doziranja u gore navedenim ispitivanjima koja obuhvaćaju 83 pacijenta upućuju na to da smjernice doziranja za odrasle vrijede i za novorođenačku i pedijatrijsku populaciju.
Dosages should be increased gradually from a starting-dose of 0.264 mg of base (0.375 mg of salt) per day and then increased every 5 - 7 days.
Dozu je potrebno postupno povisivati od početne doze 0,264 mg baze (0,375 mg soli) dnevno, svakih 5-7 dana.
dose
doza od 5
Dose
Doziranje
DOSE
DOZIRANJE:
dose
dozu
dose
niženu dozu
dose
NP
dose
pojedinačna
dose (0.5 ml)
doza (0,5 ml)
dose (0.5 ml) contains:
doza (0,5 ml) sadržava:
dose (100 microlitres) contains fentanyl citrate equivalent to 100 micrograms (mcg) fentanyl
doza (100 mikrolitara) sadrži fentanilcitrat što odgovara 100 mikrograma (μg) fentanila.
dose (100 microlitres) contains fentanyl citrate equivalent to 200 micrograms (mcg) fentanyl
doza (100 mikrolitara) sadrži fentanilcitrat što odgovara 200 mikrograma (μg) fentanila.
dose (100 microlitres) contains fentanyl citrate equivalent to 50 micrograms (mcg) fentanyl
doza (100 mikrolitara) sadrži fentanilcitrat što odgovara 50 mikrograma (μg) fentanila.
Dose (IU) = body weight (kg) x desired Factor VIII rise (% of normal) x 0.5 If you have the impression that the effect of ADVATE is insufficient, talk to your doctor.
Doza (IU) = tjelesna težina (kg) x željeni porast faktora VIII (% od normalne vrijednosti) x 0,5 Ako imate dojam da je učinak lijeka ADVATE nedostatan, obratite se svom liječniku.
Dose (IU/k g)
Doza (IU/kg)
Dose (mg/day) (a)
Doza (mg/dan) (a)
Dose (ml/kg)
Doza (ml/kg)
Dose (U)
Doza (U)
Dose 3
3. doza
Dose : ........mg twice daily
Doza: ........mg dvaput na dan
Dose [ml]
Doza (ml)
Dose absorbed per activity administered (µGy/MBq)
Apsorbirana doza po primijenjenoj aktivnosti (µGy/MBq)
Dose absorbed per activity administered [mGy/MBq]
Apsorbirana doza po primijenjenoj aktivnosti
Dose adjustment (Days 1-21 of repeated 28- day cycles)
Prilagodba doze (od 1. do 21. dana u ponavljajućim 28-dnevnim ciklusima)
dose adjustment (see
u pojedinog bolesnika (vidjeti
Dose Adjustment Based on Clinical Signs / Pathology
Prilagodba doze na temelju kliničkih simptoma/patologije
Dose adjustment based upon age is not required (see section 5.2).
Prilagodba doze s obzirom na dob nije potrebna (vidjeti dio 5.2)
Dose adjustment during post-transplant period in adults and paediatric patients
Prilagodba doze u poslijetransplantacijskom razdoblju u odraslih i pedijatrijskih bolesnika
Dose adjustment for adverse reactions
Prilagodba doze lijeka zbog nuspojava
Dose adjustment for adverse reactions in adult patients General
Prilagodba doze u slučaju nuspojava u odraslih bolesnika Općenito
Dose adjustment for adverse reactions in all indications in adults and paediatric patients
Prilagođavanje doze zbog nuspojava u svim indikacijama za odrasle i pedijatrijske bolesnike
Dose adjustment for adverse reactions in paediatric patients
Prilagodba doze u slučaju nuspojava u pedijatrijskih bolesnika
Dose adjustment for adverse reactions Non-haematological adverse reactions
Prilagođavanje doze zbog nuspojava Nehematološke nuspojave
Dose adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered.
Treba razmotriti prilagođavanje doze midazolama, posebno ako se primjenjuje više od jedne doze midazolama.
Dose adjustment for patients taking moderate CYP3A inhibitors
Prilagodba doze za bolesnike koji uzimaju umjerene inhibitore CYP3A
Dose adjustment for patients taking strong CYP3A inhibitors
Prilagodba doze za bolesnike koji uzimaju jake inhibitore CYP3A
Dose adjustment for patients with renal or hepatic impairment has not been studied in clinical trials.
Prilagodba doze za bolesnike s oštećenjem funkcije bubrega ili jetre nije ispitana u kliničkim ispitivanjima.
dose adjustment has not been
doze nije istraživana kod bolesnika s
Dose adjustment in accordance with the information stated below.
Prilagodba doze u skladu s dolje navedenim podacima.
Dose adjustment in patients with renal impairment is not necessary (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije bubrega (vidjeti dio 5.2).
Dose adjustment in the alirocumab groups to 150 mg Q2W occurred at week 12 in patients with LDL-C ≥70 mg/dL or ≥100 mg/dL, depending on their level of CV risk, or in patients who did not have at least a 30% reduction of LDL-C from baseline.
Prilagodba doze na 150 mg svaka 2 tjedna dogodila se u 12.tjednu u skupinama s alirokumabom u bolesnika s vrijednostima LDL- C ≥70 mg/dl ili ≥100 mg/dl, ovisno o njihovom kardiovaskularnom riziku, ili u bolesnika koji nisu imali barem 30% smanjenja vrijednosti LDL-C od početne vrijednosti.
dose adjustment is necessary for
prilagođavati dozu rifampicina.
Dose adjustment is not considered necessary in subjects with reduced UGT1A1 activity due to genetic polymorphism.
Smatra se da nije potrebno prilagođavati dozu lijeka u bolesnika sa smanjenom aktivnošću UGT1A1 enzima zbog genetskog polimorfizma.
Dose adjustment is not needed in patients with renal impairment (see section 5.2).
Bolesnicima s oštećenjem bubrega nije potrebno prilagoditi dozu (vidjeti dio 5.2).
Dose adjustment is not normally required; however, leucocyte cystine levels should be monitored.
Prilagodba doze obično nije potrebna; međutim, treba pratiti razinu cistina u leukocitima.
Dose adjustment is not normally required; however, WBC cystine levels should be monitored.
Obično nije potrebno prilagoditi dozu; međutim, moraju se nadzirati razine cistina u leukocitima.
Dose adjustment is not recommended for patients with mild hepatic impairment based on the results of a population pharmacokinetic analysis.
Ne preporučuju se prilagođavanja doze za bolesnike s blagim oštećenjem jetre na temelju rezultata populacijske farmakokinetičke analize.
Dose adjustment is not required in elderly patients.
Nije potrebno prilagođavati dozu u starijih bolesnika.
Dose adjustment is not required in patients with increased CYP2D6 activity, referred to as ultra-rapid metabolisers (UMs), see section 5.2. In the event of inadequate clinical response, see recommended dose titration schedule.
Prilagodba doze nije potrebna u bolesnika s povećanom aktivnošću enzima CYPD2D6, koji se nazivaju ultrabrzi metabolizatori, vidjeti dio 5.2. U slučaju neodgovarajućeg kliničkog odgovora, vidjeti preporučeni raspored titracije doze.
Dose adjustment is not required in patients with mild to moderate liver impairment.
Nije potrebno prilagođavati dozu u bolesnika s blagim do umjerenim oštećenjem jetrene funkcije.
Dose adjustment is not required in these circumstances.
U tim okolnostima ne treba prilagođavati.
Dose adjustment is recommended for both treatment and prevention in adolescents (13 to 17 years or age) and adults with severe renal impairment.
Prilagodba doze preporučuje se za liječenje i prevenciju gripe u adolescenata (u dobi od 13 do 17 godina) i odraslih osoba s teškim oštećenjem funkcije bubrega.
Dose adjustment is recommended for patients with moderate and severely impaired hepatic function (Child-Pugh Class B and C) (see sections 4.2 and 5.2).
Prilagodba doze preporučuje se u bolesnika s umjerenim i teškim oštećenjem jetrene funkcije (Child-Pugh stadij B i C) (vidjeti dijelove 4.2 i 5.2).
Dose adjustment is recommended for patients with moderate and severely impaired renal function and in patients with ESRD.
Preporučuje se prilagodba doze u bolesnika s umjerenim i teškim oštećenjem bubrežne funkcije i u bolesnika sa završnim stadijem bolesti bubrega.
Dose adjustment may also be required, for example, if
Prilagodba doze može također biti potrebna, primjerice, ako:
Dose adjustment may also be required, for example, if
Prilagodba doze može također biti potrebna, primjerice,:
Dose adjustment may also be required, for example, if the patient's weight or life-style changes, change of timing of insulin dose or other circumstances arise that increase susceptibility to hypo-or hyperglycaemia (see section 4.4).
Dozu će možda trebati prilagoditi i ako, primjerice, dođe do promjena tjelesne težine ili životnih navika bolesnika, ako se promijeni vrijeme primjene doze inzulina ili nastupe druge okolnosti zbog kojih se povećava sklonost hipoglikemiji odnosno hiperglikemiji (vidjeti dio 4.4).
Dose adjustment may be necessary (see section 4.4).
Može biti potrebna prilagodba doze (vidjeti dio 4.4).
Dose adjustment may be necessary if a patient starts or stops smoking or when concomitant treatment with strong CYP1A2 inhibitors is initiated or discontinued.
Možda će biti potrebna korekcija doze lijeka ako bolesnik počne ili prestane pušiti, ili ako počne ili prekine istodobno liječenje snažnim inhibitorima CYP1A2.
Dose adjustment may be necessary.
Može biti potrebna prilagodba doze.
Dose adjustment not required.
Prilagodba doze nije potrebna.
Dose adjustment of buprenorphine may not be necessary when co-administered with Atripla.
Kada se buprenorfin primjenjuje istovremeno s Atriplom, prilgođavanje doze buprenorfina možda neće biti potrebno.
Dose adjustment of buprenorphine or efavirenz may not be necessary when co- administered.
Pri istodobnoj primjeni možda neće biti potrebna prilagodba doze buprenorfina ili efavirenza.
Dose adjustment of cinacalcet may be required if a patient receiving cinacalcet initiates or discontinues therapy with a strong inhibitor (e.g. ketoconazole, itraconazole, telithromycin, voriconazole, ritonavir) or inducer (e.g. rifampicin) of this enzyme (see section 4.4).
Korekcija doze sinakalceta može biti potrebna kod bolesnika liječenih sinakalcetom u kojih se počinje ili prekida terapija snažnim inhibitorom (npr. ketokonazol, itrakonazol, telitromicin, vorikonazol, ritonavir), ili induktorom (npr. rifampicin) navedenog enzima (vidjeti dio 4.4).
Dose adjustment of cinacalcet may be required.
Može biti potrebna prilagodba doze
Dose adjustment of dabigatran may be required to obtain the
Može biti potrebna prilagodba doze dabigatrana kako
Dose adjustment of each drug may be required.
Može biti potrebna prilagodba doze pojedinih lijekova.
Dose adjustment of maraviroc is recommended when maraviroc is co-administered with CYP3A4 inhibitors and/or inducers.
Preporučuje se prilagoditi dozu maraviroka kod istodobne primjene s inhibitorima i/ili induktorima CYP3A4.
Dose adjustment of medicinal products that are P-gp substrates, especially medicinal products with a narrow therapeutic index such as digoxin, colchicine and dabigatran etexilate, may be needed when concomitantly administered with CRESEMBA (see section 4.5).
Prilagodba doze lijekova koji su supstrati za P-gp, a naročito lijekova s uskim terapijskim indeksom poput digoksina, kolhicina i dabigatraneteksilata, moţe biti potrebna kada se ti lijekovi primjenjuju istodobno s lijekom CRESEMBA (vidjeti dio 4.5).
Dose adjustment of Mimpara may be required if a patient receiving Mimpara initiates or discontinues therapy with a strong inhibitor (e.g. ketoconazole, itraconazole, telithromycin, voriconazole, ritonavir) or inducer (e.g. rifampicin) of this enzyme (see section 4.4).
Korekcija doze Mimpare može biti potrebna kod bolesnika liječenih Mimparom u kojih se počinje ili prekida terapija snažnim inhibitorom (npr. ketokonazol, itrakonazol, telitromicin, vorikonazol, ritonavir), ili induktorom (npr. rifampicin) navedenog enzima (vidjeti dio 4.4).
Dose adjustment of paclitaxel may be required.
Može biti potrebna prilagodba doze paklitaksela .
Dose adjustment of ranitidine may be
Može biti potrebna prilagodba doze
Dose adjustment of risperidone may be required.
Može biti potrebna prilagodba doze risperidona.
Dose adjustment of the background opioid therapy may be required if the patient consistently presents with more than four breakthrough pain episodes per 24 hours.
Ukoliko se uzastopno javlja više od četiri epizode probojne boli u 24 sata, možda je potrebna prilagodba doze trajne opioidne terapije za kroničnu bol.
Dose adjustment of these drugs may be required.
Može biti potrebna prilagodba doze ovih lijekova.
Dose adjustment of warfarin or acenocoumarol may be required when co-administered with Atripla.
Kada se varfarin ili acenokumarol primjenjuju istovremeno s Atriplom, možda će biti potrebno prilgođavanje njihove doze.
Dose adjustment of warfarin or acenocoumarol may be required.
Nije potrebno prilagođavati dozu ni jednog od ovih lijekova.
Dose adjustment or response
Prilagodba doze ili odgovora
Dose adjustment should be considered based on the patient’s clinical response to methadone therapy.
Dozu treba prilagođavati ravnajući se bolesnikovim kliničkim odgovorom na primjenu metadona.
Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient.
O podešavanju doze odlučuje liječnik, na osnovu ocjene potencijalnih pozitivnih učinaka i rizika za pojedinog bolesnika.
Dose adjustment should be decided at the discretion of the physician, following assessment of the potential benefit and risk to an individual patient.
O prilagođavanju doze odlučuje liječnik, na osnovu ocjene potencijalnih pozitivnih učinaka i rizika za pojedinog bolesnika.
Dose adjustment to maintain haemoglobin concentrations between 10 g/dl to 12 g/dl (6.2 to 7.5 mmol/l)
Prilagodba doze radi održavanja koncentracije hemoglobina između 10 g/dl i 12 g/dl (6,2 i 7,5 mmol/l)
Dose adjustment was possible in the case of adverse events.
Prilagodba doze bila je moguća u slučaju štetnih događaja.
Dose adjustment with concomitant strong CYP3A4 inhibitors or fluconazole
Prilagođavanje doze kod istodobne primjene snažnih CYP3A4 inhibitora ili flukonazola
Dose Adjustment*
Prilagodba doze
Dose adjustment:
Prilagodbe doze:
Dose adjustment: Filgrastim should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 x 109/l.
Prilagodba doze: Filgrastim treba davati svakodnevno supkutanom injekcijom sve dok broj neutrofila ne dosegne 1,5 x 109/l i dok se ne bude održavao najmanje na toj vrijednosti.
Dose adjustment: Grastofil should be administered daily by subcutaneous injection until the neutrophil count has reached and can be maintained at more than 1.5 x 109/L.
Prilagodba doze: Grastofil je potrebno primjenjivati svakodnevno supkutanom injekcijom sve dok broj neutrofila ne poraste i održi se iznad vrijednosti od 1,5 x 109/l.
Dose adjustment: If Atripla is co-administered with rifampicin to patients weighing 50 kg or more, an additional 200 mg/day (800 mg total) of efavirenz may be considered (see section 4.5).
Prilagođavanje doze: Ako se Atripla istovremeno primjenjuje s rifampicinom u pacijenata tjelesne težine 50 kg ili više, može se uzeti u obzir davanje dodatnih 200 mg efavirenza dnevno (ukupno 800 mg) (vidjeti dio 4.5).
Dose adjustments and other considerations for safe use
Prilagođavanje doze i druge mjere za sigurnu primjenu
Dose adjustments are based upon the platelet count response.
Prilagodbe doze su bazirane na odgovoru prema broju trombocita.
Dose adjustments are not required for patients receiving regularly scheduled haemodialysis (3 times/week), and dalbavancin may be administered without regard to the timing of haemodialysis.
Nije potrebno prilagođavanje doze za bolesnike koji redovito primaju hemodijalizu (3 puta u tjednu) i dalbavancinse može davati bez obzira na vrijeme primanja hemodijalize.
Dose adjustments are not required for patients with mild or moderate renal impairment (creatinine clearance  30 to 79 ml/min).
Nije potrebno prilagođavanje doze za bolesnike s blagim ili umjerenim oštećenjem bubrega (klirens kreatinina  30 do 79 ml/min).
Dose adjustments are not required in diabetic patients.
Nije potrebno prilagođavati dozu u bolesnika sa šećernom bolešću.
Dose adjustments are not required in diabetic patients.
U muškaraca s dijabetesom nisu potrebne prilagodbe doze.
Dose adjustments are not required in older patients.
U starijih bolesnika nisu potrebne prilagodbe doze.
Dose adjustments are not required in patients with mild to moderate renal impairment.
U bolesnika s blagim do umjerenim oštećenjem bubrežne funkcije nije potrebno prilagođavati dozu.
Dose adjustments are recommended for patients with hepatic impairment (see section 4.2).
Preporučuje se prilagoditi dozu u bolesnika s oštećenjem jetrene funkcije (vidjeti dio 4.2).
Dose adjustments are required for children aged from 2 months to < 12 years and for adolescents aged 12 to < 18 years with bodyweight < 33 kg (see section 4.2).
Potrebne su prilagodbe doze u djece u dobi od navršena 2 mjeseca do <12 godina i u adolescenata u dobi od navršenih 12 do <18 godina koji imaju tjelesnu težinu <33 kg (vidjeti dio 4.2).
Dose adjustments do not need to be made for weight changes of ≤ 20%.
Prilagodba doze nije potrebna za promjene tjelesne težine ≤ 20%.
Dose adjustments do not seem to be necessary when imatinib is co-administrated with CYP2D6 substrates, however caution is advised for
Izgleda da prilagođavanje doze nije neophodno kada se imatinib istodobno primjenjuje sa supstratima CYP2D6, međutim, savjetuje se oprez kod supstrata
Dose adjustments due to toxicity
Prilagodbe doze zbog toksičnosti
Dose adjustments during treatment and re-initiation of treatment for monotherapy
Prilagodbe doze za vrijeme i kod ponovnog uvođenja monoterapije
Dose adjustments during treatment for patients with previously untreated mantle cell lymphoma
Prilagodbe doza tijekom liječenja za bolesnike s prethodno neliječenim limfomom plaštenih stanica
Dose adjustments for co-administration with CYP3A inhibitors
Prilagodba doze zbog istodobne primjene inhibitora CYP3A
Dose adjustments for CYP3A4 substrates with narrow therapeutic window may be considered, if clinically indicated (see sections 4.4 and 4.6).
Može se razmotriti prilagodba doze supstrata CYP3A4 s uskim terapijskim prozorom, ako je to klinički indicirano (vidjeti dijelove 4.4 i 4.6).
Dose adjustments for haematologic adverse reactions
Prilagođavanja doze zbog hematoloških nuspojava
Dose adjustments for medicinal products predominantly metabolised via CYP1A2 or CYP3A4 should be considered based on their therapeutic windows before concomitantly treating with vemurafenib (see sections 4.5 and 4.6).
Prije početka istodobne primjene s vemurafenibom potrebno je razmotriti prilagodbu doze lijekova koji se pretežno metaboliziraju putem CYP1A2 ili CYP3A4 na temelju njihova terapijskog prozora (vidjeti dijelove 4.5 i 4.6).
Dose adjustments for non-haematologic adverse reactions
Prilagođavanja doze zbog nehematoloških nuspojava
Dose adjustments for prophylactic dose ranges
Prilagodbe doze za profilaktičke raspone doziranja
Dose adjustments for prophylactic dose ranges of enoxaparin sodium
Prilagodbe doze enoksaparinnatrija za profilaktičke raspone doziranja
Dose adjustments for these
utječu na farmakokinetiku
Dose adjustments for this age group should be on the basis of renal function, see section 4.2.
Podešavanje doze za ovu starosnu grupu treba temeljiti na funkciji bubrega, vidjeti dio 4.2.
Dose adjustments in 100 mg steps per day (i.e. a 50 mg reduction per dosing) based on individual safety and tolerability are recommended as described in Table 1 and Table 2.
Prilagodbe doze u koracima od 100 mg dnevno (tj. smanjenje od 50 mg po dozi), koja se temelje na individualnoj sigurnosti i podnošljivosti, preporučuju se kao što je opisano u tablici 1 i tablici 2.
Dose adjustments in patients with haematological adverse reactions
Prilagodbe doza u bolesnika s hematološkim nuspojavama
Dose adjustments in patients with renal impairment by indication and creatinine clearance
Prilagođavanje doze u bolesnika s oštećenjem bubrega, prema indikaciji i klirensu kreatinina
Dose adjustments may also need to be made in patients who are switched between Lixiana and other anticoagulant medicines.
Prilagodba doze možda će biti potrebna u bolesnika koji s lijeka Lixiana prelaze na druge antikoagulanse i obrnuto.
Dose adjustments may be made in steps of 3.5 to 7 mg/kg and are to be tailored to the individual patient’s response and therapeutic goals (maintenance or reduction of iron burden).
Prilagodbe doze, ako je potrebno, se mogu provoditi u koracima po 3,5 do 7 mg/kg vodeći računa o individualnom odgovoru bolesnika i terapijskim ciljevima (održavanje ili smanjenje opterećenja željezom).
Dose adjustments may be made in steps of 5 to 10 mg/kg and are to be tailored to the individual patient’s response and therapeutic goals (maintenance or reduction of iron burden).
Prilagodbe doze, ako je potrebno, se mogu provoditi u koracima po 5 do 10 mg/kg vodeći računa o individualnom odgovoru bolesnika i terapijskim ciljevima (održavanje ili smanjenje opterećenja željezom).
Dose adjustments of
Kod istodobne primjene s
Dose adjustments of atorvastatin may be required (refer to the Summary of Product Characteristics for the atorvastatin).
Može biti potrebno prilagođavati dozu atorvastatina (vidjeti Sažetak opisa svojstava lijeka za atorvastatin).
Dose adjustments of calcium channel blockers should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker).
Može biti potrebno prilagođavati dozu pravastatina (vidjeti Sažetak opisa svojstava lijeka za pravastatin).
Dose adjustments of calcium channel blockers when co-administered with Atripla should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker).
Podešavanja doze blokatora kalcijevih kanala kada se primjenjuju istovremeno s Atriplom treba usklađivati s kliničkim odgovorom (pogledajte sažetak opisa svojstava lijeka za blokator kalcijevih kanala).
Dose adjustments of concomitant medicinal products may be required when cinacalcet is administered with individually titrated, narrow therapeutic index substances that are predominantly metabolised by CYP2D6 (e.g. flecainide, propafenone, metoprolol, desipramine, nortriptyline, clomipramine) (see section 4.4).
Korekcija doze konkomitantnih lijekova možda je potrebna kada se sinakalcet primjenjuje s lijekovima koji se pretežno metaboliziraju tim enzimom i imaju uski terapijski raspon (npr. flecainid, propafenon, metoprolol, desipramin, nortriptilin, klomipramin) (vidjeti dio 4.4).